13F HOLDINGS REPORT
ARCH Venture Management, LLC
Quarter ended Q1 2024 · Filed May 15, 2024 · Accession 0001012975-24-000230
Total Value
$80.3M
Positions
8
Other Managers
0
Confidential Omitted
No
Holdings (8)
| # | Issuer | Ticker / CUSIP | Shares | Value | % of Filing |
|---|---|---|---|---|---|
| 1 | VERVE THERAPEUTICS, INC. | 92539P101 | 2,008,809 | $26.7M | 33.23% |
| 2 | ERASCA, INC. | ERAS | 11,055,554 | $22.8M | 28.37% |
| 3 | GOSSAMER BIO, INC. | GOSS | 8,055,916 | $9.5M | 11.84% |
| 4 | DENALI THERAPEUTICS, INC. | DNLI | 381,249 | $7.8M | 9.75% |
| 5 | Q32 BIO INC. | QTTB | 320,482 | $5.5M | 6.80% |
| 6 | CERO THERAPEUTICS HOLDINGS, INC. | 71902K105 | 1,444,296 | $4.4M | 5.52% |
| 7 | SINGULAR GENOMICS SYSTEMS, INC. | 82933R100 | 3,798,926 | $2.0M | 2.43% |
| 8 | UNITY BIOTECHNOLOGY, INC. | UNTCW | 1,004,817 | $1.6M | 2.05% |